BACKGROUND: As left ventricular assist device (LVAD) support duration increases, quality of life (QoL) becomes a concern. We reviewed the QoL in patients on LVAD support for >or=1 year. METHODS: We retrospectively reviewed our prospective database for patients supported >or=1 year by HeartMate pulsatile- (HM1) or continuous-flow (HM2) LVADs from 2000 to 2009. Transplant or death before 1 year merited exclusion. Metabolic equivalents of tasks (METs), the Minnesota Living with Heart Failure Questionnaire (MLHFQ), the 6-minute walk distance (6MWD), and New York Heart Association (NYHA) class were reviewed. Complications and re-admissions were assessed. RESULTS: Thirty patients were supported for >or=1 year (7 HM1s, 23 HM2s). Mean support duration was 594 +/- 173 days. Mean QoL metrics/functional status indicators at 12 months were: 6MWD, 393 +/- 290 m; MET tolerance, 3.3 +/- 1; MLHFQ, 35 +/- 31; and NYHA, 1.4 +/- 0.6. Mean re-admissions/year was 2.9 +/- 2, with a duration of 13.8 +/- 21 days. Three patients were never re-admitted. Mean out-of-hospital time was 471 +/- 172 days (87.3% of days). Infectious complications led to 43% of re-admissions and occurred in the: drive-line (47%) at 442 +/- 236 days; blood (37%) at 472 +/- 257 days; and LVAD pocket (20%) at 550 +/- 202 days. Twenty-three patients (77%) required additional operations (1.7 +/- 1.8/year). The most common indication was drive-line infection, but ranged from ischemic bowel to defibrillator exchange. Eight required LVAD exchanges for mechanical (n = 4), electrical (n = 3), and thrombotic (n = 1) issues. CONCLUSIONS: Although LVAD support is not without complications, patients spend the majority of time outside the hospital enjoying a good quality of life.
BACKGROUND: As left ventricular assist device (LVAD) support duration increases, quality of life (QoL) becomes a concern. We reviewed the QoL in patients on LVAD support for >or=1 year. METHODS: We retrospectively reviewed our prospective database for patients supported >or=1 year by HeartMate pulsatile- (HM1) or continuous-flow (HM2) LVADs from 2000 to 2009. Transplant or death before 1 year merited exclusion. Metabolic equivalents of tasks (METs), the Minnesota Living with Heart Failure Questionnaire (MLHFQ), the 6-minute walk distance (6MWD), and New York Heart Association (NYHA) class were reviewed. Complications and re-admissions were assessed. RESULTS: Thirty patients were supported for >or=1 year (7 HM1s, 23 HM2s). Mean support duration was 594 +/- 173 days. Mean QoL metrics/functional status indicators at 12 months were: 6MWD, 393 +/- 290 m; MET tolerance, 3.3 +/- 1; MLHFQ, 35 +/- 31; and NYHA, 1.4 +/- 0.6. Mean re-admissions/year was 2.9 +/- 2, with a duration of 13.8 +/- 21 days. Three patients were never re-admitted. Mean out-of-hospital time was 471 +/- 172 days (87.3% of days). Infectious complications led to 43% of re-admissions and occurred in the: drive-line (47%) at 442 +/- 236 days; blood (37%) at 472 +/- 257 days; and LVAD pocket (20%) at 550 +/- 202 days. Twenty-three patients (77%) required additional operations (1.7 +/- 1.8/year). The most common indication was drive-line infection, but ranged from ischemic bowel to defibrillator exchange. Eight required LVAD exchanges for mechanical (n = 4), electrical (n = 3), and thrombotic (n = 1) issues. CONCLUSIONS: Although LVAD support is not without complications, patients spend the majority of time outside the hospital enjoying a good quality of life.
Authors: Julia Hutchinson; David A Scott; Andrew J Clegg; Emma Loveman; Pam Royle; Jackie Bryant; Jill L Colquitt Journal: Expert Rev Cardiovasc Ther Date: 2008-02
Authors: A J Clegg; D A Scott; E Loveman; J Colquitt; J Hutchinson; P Royle; J Bryant Journal: Health Technol Assess Date: 2005-11 Impact factor: 4.014
Authors: Soon J Park; Alfred Tector; William Piccioni; Edward Raines; Annetine Gelijns; Alan Moskowitz; Eric Rose; William Holman; Satoshi Furukawa; O Howard Frazier; Walter Dembitsky Journal: J Thorac Cardiovasc Surg Date: 2005-01 Impact factor: 5.209
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Joseph G Rogers; Javed Butler; Steven L Lansman; Alan Gass; Peer M Portner; Michael K Pasque; Richard N Pierson Journal: J Am Coll Cardiol Date: 2007-08-06 Impact factor: 24.094
Authors: Andreas Zierer; Spencer J Melby; Rochus K Voeller; Tracey J Guthrie; Gregory A Ewald; Kim Shelton; Michael K Pasque; Marc R Moon; Ralph J Damiano; Nader Moazami Journal: Ann Thorac Surg Date: 2007-08 Impact factor: 4.330
Authors: Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller Journal: Circulation Date: 2007-07-16 Impact factor: 29.690
Authors: Nathan E Goldstein; Jill Kalman; Jean S Kutner; Erik K Fromme; Mathew D Hutchinson; Hannah I Lipman; Daniel D Matlock; Keith M Swetz; Rachel Lampert; Omarys Herasme; R Sean Morrison Journal: J Pain Symptom Manage Date: 2014-04-21 Impact factor: 3.612
Authors: Mathew S Maurer; Evelyn Horn; Alex Reyentovich; Victoria Vaughan Dickson; Sean Pinney; Deena Goldwater; Nathan E Goldstein; Omar Jimenez; Sergio Teruya; Jeff Goldsmith; Stephen Helmke; Melana Yuzefpolskaya; Gordon R Reeves Journal: J Am Geriatr Soc Date: 2017-09-21 Impact factor: 5.562
Authors: Christopher S Lee; James O Mudd; Jill M Gelow; Thuan Nguyen; Shirin O Hiatt; Jennifer K Green; Quin E Denfeld; Julie T Bidwell; Kathleen L Grady Journal: J Cardiovasc Nurs Date: 2014 Sep-Oct Impact factor: 2.083
Authors: Julie T Bidwell; Karen S Lyons; James O Mudd; Jill M Gelow; Christopher V Chien; Shirin O Hiatt; Kathleen L Grady; Christopher S Lee Journal: J Cardiovasc Nurs Date: 2017 Sep/Oct Impact factor: 2.083